Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
While Cogent joins the FGFR party.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Just when investors thought things couldn't get any worse, they do.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
